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H~~resPltshdramaticChMg~iIlCCrEoian~ 
mitter and Immune receptors. The mqjority of the changes occur 
intbeheartandgeaerallycanbeclassiWasregulatoryphenom- 
ella that withdraw the failing heart from adrelleqgc stimldatiou. 
Of these, the most prominent is be&-receptor d wnregulatIon. 
Changesiuv~larreceptopsaremuchI~promineataudtliere 
ir no dii evidence that any vascuk receptor chauges ic heart 
fkihlre. 
The change5 that accur in myucardii receptors suggest that 
Myocardial Receptors 
One way to approach the failing heart is to subdivide 
myocardial performance into the subcellular components 
that deal with intrinsic and stim&ed function. The heart 
can be considered to have a basal evel of systolic and 
diastolic function that maintains the circulation under est 
conditions and a sLprate specialized function that is respon- 
sible for the ability of the heart to increase markedly its 
performance n arly instantaneously in response to stress or 
exercise. As s&own in Table 1, the elements responsible for 
intrinsic function can be generally categorized into the 
contractile proteins and the various processes that are re- 
sponsible for excitation-contraction c upling. In addition, 
because of the obvious survival advantage, the human heart 
has evolved highly specialized and redundantly regulated 
systems to mediate stimulated function. These are a dense 
adrenergic innervation, adrenergic receptor-eE’ector mecha- 
nisms and a prominent force-frequency response (Table 1). 
Only in advanced heart fa&ue are symptoms or de 
creased cardiac output present u der est conditions. This is 
because the intrinsic abnormality orabnormalities in myo- 
cardial function are matched by activation f compensatory 
mechanisms that collectively maintain central blood pres- 
sure and cardiac output. These compensatory mechanisms, 
some of which are in the “Stimulated Function” category in 
the Table 1, are given i  Figure 1. They include increased 
heart rate, increased contractility mediated by beta- 
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adrenergic mechanisms and increased tilling pressure medi- 
ated by the renin-angiotensin sy tem. In less advanced heart 
failure, sympt-ms and cardiac output abnormalities appear 
only when the heart is stressed; that is, when it uses the 
specialized subcelhdar mechanisms subserving stimulated 
cardiac fuaction. 
As is discussed elsewhere in this symposium by Poole- 
Wilson et al. (11, despite years of work in multiple laborato- 
ries, there is no consensus as to the natum of an intrinsic 
defect in mechanical function in common kinds of nonstruc- 
tural cardiomyopathy, such as the idiopathic dilated type. 
Conversely, several discrete molecular abnormalities have 
not been identified in stimulated cardiac function. These 
primarily reside in the betaaergic receptor-G protein- 
adenylyl cyclase pathway, but also include an abnormality in 
at least one phospholipase C pathway and a defective 
force-kquency response (2,3). The components of the 
beta-adrenergic re eptor-G protein-adenylyl c clase path- 
way and the alpha,-adrenergic-phospholipase pathway, all of 
which are cou@A to a positive inotropic response inhuman 
ventricular myocardium, are shown in Figure 2. 
Cardia~a&ene@cactivationinheartfaihu~ AsThames 
et al. (4) emphasize elsewhere in this symposium, there is 
activation of the sympathetic nervous ystem in heart fail- 
ure. There are some interesting pharmacologic implications 
of this activation that need to be discussed before delineation 
of receptor pathway changes. The first point is that cardiac 
as well as system adreaergic drive are activated in heart 
faia. The endogenous beta-agonist invoIved in this activa- 
tion is norepinephrine, the neurotransmitter in mammaik 
myocardium. Norepinephrine is a beta,-selective agonist 
and is M-fold selective for beta,- versus be&receptors and 
l&fold selective for beta,- versus alpha,-receptors (s).Prom 
a cardiac standpoint, norepinephrine is not a very @ 
hormone because it is taken up by the neuronal uptake 
0735-!O!W/?M6.~ 
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system as arteriai levels traverse the heart. However, f om a 
systemic standpoint, hormonal nomphtephrine exported 
from the failing heart by means ofneurotransmitter spiiiover 
constitutes 30% to 50% of the circuiating pool (a). This 
hormonai norepinephrine is available to bind to betat- 
adrenergic receptors present intissues that Lack a neuronai 
uptake system, such as fat ceiis. The primary adrenergic 
hormone in humans is epinephtine, which is a nonselective 
agonist. Inheart faiiure, circuiating epinephrine s increased 
much less than is norepinephrine, although if one comhmes 
aii studies that have measured pinephrine  heart 1.&e 
there is a two to three-foid ncrease. Epinephriue is also 
taken up by the neunmai uptake system, with siightiy less 
a&ity than norepinephrine (7). The apparent purpose of 
adrenergic hormones is to interact with adrenergic re eptors 
that reside outside the synaptic cleft, away from the neuro- 
nai uptake system. These hormonaiiy responsive receptors 
in&de beta&renergic receptors in the heart (8,9), aiphax- 
receptors in vascuiar smooth muscle and beta,- and alphal- 
receptors in noniMervated issue. 
Admergh reaptor pathways. From the standpoint of 
catechoiamines, siguais are transduced by two different 
pathways (Fig. 2). In myocardiai ceiis, there are three 
different adrenergic re eptor subtypes coupled tothese two 
signai transduction pathways. The two signai transduction 
pathways are the adenyiyi cyciase pathway and the phos- 
phoiipase C pathway. As shown in Figure 3, proximaiiy 
positioned to the adenyiyi cyciase pathway are beta,- and 
beh&‘emgic receptors coupled through a heteronimeric 
G protein G,. In the human heart, both beta,- and betas- 
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receptors are functionally preseut (9,101, and in the Ming 
heart roughiy 40% of the receptors are of the beta, variety 
(9). These agonist occupied receptors act by increasing the 
catalytic rate of adenyiyi cyciase to form more cyclic ade- 
nosine monophosphate (AMP). Bet+-receptors mediate a 
much greater degree ofadenyiyi cyciase stimuiation (1411) 
than do betas-receptors, but the degree of stimuhuion f 
muscle contraction is the same for betat- and be@-receptors 
(9) and in direct proportion totheir elative densities. Ai- 
phat-receptors are present in the human heart in much lower 
density than beta-receptors andare coupled to a weak 
positive inotropic response tbrough the effector phospho- 
iipase C (5). The phosphoiipase C pathway is interesting 
inasmuch asthere am resiiy two second messengers: diacyi- 
giyceroi and inositoi triphosphate. This iatter second mes- 
senger causes calcium release from the sarcopiasmic reticu- 
lum and a subsequent i crease in contractiiity in both 
myocardiai nd vascuiar smooth muscle. Diiigyiceroi 
mediates protein kinsse C activation i the membrane, 
which then activates protoonwgene expression, leading to 
both myocardii and vascuiar ceii growth. Importantiy, 
recent data indicate that adrenergic receptors coupled to 
adeqiyi cyciase or phosphoiipase C may participate in 
cross-regulatory phenomena, or %osstaik.” That is, in 
model systems bearing both be&- and alpha,-receptors, 
beta-receptor s imulation r postreceptor activation f ade- 
nyiyi cyciase can upreguiate lpha,-receptor messenger ri- 
bonucieic a id @RNA) (12), afinding that may have signif- 
icance for the failing human heart. 
Figure 3iilustrates that he adenyiyi cyciase signal tr ns- 
duction pathway ic qute cot~~‘Wzd. There are a number of
membrane receptors coupled to G,, the stimuiatory G pro- 
tein; tbe ones we have studied in the human heart are shown. 
They aii lead to an increase in cyclic AMP formation and 
then to increased wntmctiiity b  activation f protein kinase 
A and the subsequent phosphoryiation of target s ructures 
such as calcium channels, which causes increased caicium 
inilux. Mike for the aipha,-receptor-phosphoiipase C that 
pathway, leads to enbsnced contraction in both cardii and 
vascuiar smooth muscle, cyclic AMP causes vasodiiation by 
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FIgwe 2. The three adrenergic receptors 
coupled to two positive inotropic effector 
enzymes inthe cell surface membrane of 
human ventricular myocytes. AC = ade- 
nylyl cyclase; ATP = a&no&e tiphos- 
phate; CAMP = cyclic adenosiae man* 
phosphate; BG= diacylglycerok GDP = 
guanosine diphosphate; GTP = guanosine 
tiphosphate; IP3 = inositol triphosphate; 
PIP2= phosphatidylinositol; PLC = 
phospholipase C. 
means of phosphorylation of myosiu light chain kinase. On 
the other side of the equation (Ftg. 3) are receptors coupled 
to Gi, the inhibitory Gprotein. Occupancy of these receptors 
by agonists leads to inhibition of cyclic AMP formation and 
a negative inotropic response. 
Myocar&lreceptorregulaBoninheartbrilure. Sev ralof 
the receptors and G proteins hown in Figure 3 undergo 
changes in the chronically failing human heart. These are 
described inTable 2. The beta,-receptor downregulates (that 
is, decreases iu density) (9). The betas-receptor does not 
change iu amount or density, but exhibits mild uncoupling 
from functioruil response (10). The Iis histamine receptor 
does not appear to change (13,14). The vasoactive & stinal 
peptide (VLP) receptor dowuregtdates substantially b I% 
(15). G, does not change (16,17) and Gi increases in func- 
tional activity (16,17) but apparently not in a significant 
amount (18). Surprisingly, the receptors coupled to Gi do not 
appear to change iu heart failure (19-21). Only in situations 
of pressure overload oes the activity of the catalytic unit of 
adenylyl cyclase change (1722). Therefore, there are numer- 
ous discrete changes in these signal tsansduction pathways 
in heart failure. 
Table 3 underscores three aor points regardii tbe G 
protein-adenylyl c clase pathway. The G protein-adenylyl 
cyclase pathway is the means by which myouudial perfor- 
mance is changed rapidly, and the beta-G proW-adenyl~~ 
Figure 3. The receptor-G protein- 
adenylyl cyclase (AC) pathway in 
the cell surface membrane of hu- 
man ventzicuhw myocytes. Be- 
ceptors not shown coupled to G, 
aretheVIPand&receptorsand 
COUpled t0 Gi the SOmatOS&U 
receptor.) A-RINASE = proteiu 
kinase A. Ca” 
PLMBN ‘= 
= calcium. 
phospholambani 
PDE = phosphediesterase; SR = 
sarcoplasmic reticulum; other ab 
breviations as in Pii 2. 
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Title a Changes In Receptors, G Roteins and Ehtor hWeS and ejection fraction ,0.40 and subjects with severe heart 
intheFailing~~HeartbyTypeofHearsMuscleDisease f ilure and ejection &action CO.25 As can be seen, there is 
%zz!!F 
a marked reduction i  the dobutamine contractility response 
Iscllcmic Frcssure in subjects with advanced heart failure. After dobutamine s 
Abmnmnlity cardIomyopatby cerdiopnyopgtby hrkad 
-z- ++ + +tt 
-rnccptar- 0 tt 0 
Be- t t t 
hCES!XdIlCtiVItyOfGi t t ? 
Llemmd kxaytic alaity 0 0 t 
of4ae941 CM 
~nceptordowmeeulation t+ .. ? ? 
vIP=vasoadi~illtcstieaipcptidc. 
cyclase pathways exert a very powerful positive inotrrpic 
effect in the human heart. In the innervated heart, contrac- 
tibtycanbeincreasedliterallyinamatterofsecondsby 
occupancy of heta-adrenergic receptors. Another important 
point about his system is that in heart failure chronic 
activation of adrenergic drive is potentially cardiotoxic, 
possibly by overloading the cell with calcium and subse- 
quent adverse effects on macromolecular synthesis (23). A 
final, more pharmacol@c, point is that because the beta-G 
protein-adenylyl cyc ase system is such apowerful regulator 
of contractility and it is potentially cardiotoxic, it is highly 
and redundantly regulated. 
As shown i  Pii 4, the desensitization changes involv- 
ing the hetaG protein+tdenylyl c clase pathway lead to an 
attenuation of the systolic tension response to beta-agonists, 
including isoproterenol and dobutamine and the phosphodi- 
e&erase inhibitor enoximone, but not to the sodium channel 
agonist BDF-914% as first reported by Schwinger et al. (24). 
Beta-agonist responses are decreased because of Ma,- 
receptordownregolation, receptor uncoupling and increased 
tonic inhiMed by Gr, whereas phosphodiesterase i&&or 
responses are decreased because there is less substrate 
cyclic AMP available asa result of the collective desensiti- 
xation process. 
As was mentioned, the specific -ties in stimu- 
lated cardiac function i volving the G protein-adenylyl cy- 
clase system can be demonstrated in the intact human heart. 
Pii 5 gives data on contractility estimated by first deriv- 
ative of left ventricular pressure (dP/dt) measurements with
a left ventricular Mii catheter during dobutamine i fitsiou 
(25). AS shown in Figure 4, dobutamine s anonselective 
partial agonist in human ventricular myocardium, with an 
intrinsic activity of around 0.5 (26). The two groups of
SUbjects~Figure5arethosewi~noormildheartfailure 
wash& out and calcium isinfused, there is no difference in 
contractility response between control and failing hearts. 
Another point o be made here is that even though dobu- 
tamine isa partial agonist, the degree ofincrease in systolic 
performance conferred by it is still substantial and compa- 
rable to the calcium increase in failing heart. In other words, 
the beta-adrenergic pathways are very powerful enhancers 
of contractility, even when beta-adrenergic activity is par- 
tially lost in heart failure. 
Pii 6 gives direct measurements of right ventricular 
myocardial adrenergic receptors in three types of material. 
One source ismyocardial membranes prepared from nonfail- 
ing control organ donors with normal echocardiograms who 
were not used for transplantation andwho had not heen 
subjected to high doses of beta-agonists. Another group is 
heart failure from idiopathic dilated cardiomyopathy with 
severe right ventricular dysfunction. A third group is heart 
faihue from severe pressure overload due to primary pulmo- 
nary hypertension, with an average pulmonary artery pres- 
sure of 57 mm Hg (22). If one measures heta+lrenergic 
receptors in these three conditions, there is a marked e- 
crease indensity in idiopathic cardiomyopathy andan even 
greater decrease in beta,density n the ~sure overloaded 
right ventricle. As can be seen, the beta2-receptor opulation 
is not different across these two types of heart faihure, 
whereas lpha&energic receptor population is if anything 
slightly increased. Therefore, from the standpoint of adren- 
ergic receptors that mediate contractility ncreases, only one 
of them, the beta,-subpopulation, is decreased in the failing 
human heart. As shown in Pii 6, the left ventricular 
receptor data from the same groups reveal an interesting 
phenomenon. Note in Pii 6 that the downregulation of 
be&-receptors in the right ventricle ofsubjects with primary 
pulmonary h pertension (Fig. 5) is not observed in the 
nonfailing lefi ventricle from these subjects (22). The sub- 
jects with primary pulmonary h pertension shown i  Figure 
7 have normal left ventricular function echocardiographi- 
tally, and Mat-receptor density is normal despite severe 
da33 III to IV heart failure symptoms and elevated systemic 
norepinephrine lev ls (22). Piire 7 demonstrates that as for 
down-regulation of be&-receptors, ti sue norepinephrine 
depletion (aconsequence of adrenergic a tivation) is also 
conlined tofailing chambers and is not present innonfailing 
chambers ven when the clinical syndrome of heart faihrre is
pres nt. Therefore, the adrenergic &ormalities, which our 
group and others have described in the failing human heart, 
are strictly congned tofailing chambers. 
The diminished &al-receptor population i  the Ml& 
human heart has important implications for adrenergic 
signdii. Nonfailing myocardium, because of the large 
majority of heta+ceptors, is operationally a be&receptor 
organ. Conversely, because of the selective loss of beta,- 
T* 3. Importance of the Beta-Receptor-G protein-Adenylyl 
Cyclase pathway i  the Human Heart 
MoatYowafal~oflcglMlscootractiiity 
-ifdV8tedcbronicslly 
Hbllry~rrdunQntlYregulsted 
JACC Vol. 22. No. 4 (Supplement A) 
October 1993:61A-71A BKUSTOW BECEFiOKS IN iSART FAiiiiRE 
6SA 
2500 
1 
P NF.n.4-46 
m F.n.12-25 ‘.PC.o5 
Figure 4. Systolic tension response to the beta-agonists d
isoproterenol (ISO) and dobutamine (DBT), the phosphodi- 
esterase inhibitor enoximone (ENOX), calcium (Ca), forsko- 
% 
lin (FORSK) and the sodium channel agonist BDF-91J8 in 
E 
g 
isolated right ventricular t abeculae taken from nonfailing 
(NF) and failing (Fl human hearts. 
g 
3 
5 
P 
receptors, failing myocardium becomes a mixed system 
with be&- and alpha,-receptors now accounting for more 
thr i 50% of the population. Therefore, if one wants to 
address heart muscle therapeutically by adrenergic stimula- 
tion or blockade, the approach s ould be different for failing 
versus nonfailing myocardium. In nonfailing myocardium, 
the be&-receptor population dominates nd beta,-selective 
antagonists (or agonists) would give results similar to non- 
selective beta- or combined bedalpha-blockade. In con- 
trast, in failing myocardium, one should take into account 
that two r even three adrenergic receptors are present, with 
beta,-receptors and alpha,-receptors ccupying a majority of 
the adrenergic receptor population. The increase in the 
relative importance of the betas-population in thefailing 
heart can be seen in Figure 8, which are pooled data from a 
large number of nonfailing and failing human I& and right 
ventricles. In advanced heart failure (B-10,17) as shown in 
Figure 5. Comparison of the positive inotropic re- 
sponse of the partial beta-agonist dobutamine or cal- 
cium in subjects with advanced heart failure (Group B) 
or control subjects with no heart failure (Group A). 
Reproduced from Fowler et al. (25) with permission f 
The American Heart Association. dP/dT = first deriv- 
ative of left ventricular p essure. 
NET 
INCNEA5E 
dPldT 
(mm Hglsec’ 
_ 
I90 MT mox Q ‘FCRS BDF-9146 
Figure 8 or in aged myocardium (27), the beta,-population is 
35% to 40% of tne total population of beta-adrenergic 
receptors. Therefore, if one is to address human myocardial 
beta-adrenergic eceptors tbnapeutically with either agonist 
or antagonists, nonselective agents are ~~ssary to provide 
maximal effects. 
The beta,-receptor p pulation, although not decreased in 
density, is mildly uncoupled from pharmacologic response in
failing myocardium. Figure 9 gives beta+ceptor density 
compared with subtype selective stimulation of adenylyl 
cyclase and muscle contraction i subjects with idiopathic 
dilated cardiomyopathy and no&iling control subjects. It
can be seen that despite the lack of a decrease in beta,- 
receptor density, there is an apparent reduction in beti+- 
receptor mechanical nd functional responses. The involve 
ment of beta+ceptors in desensitization phenomena likely 
means that the receptor pathway is mediating some of the 
1600 
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ALPHA.1 
RIGHT VERTRICLES 
m NF,n-12 
0 IDC.ll-24 
n PPH.n-12 
‘, p < .OS vs NF 
” TOTALBETA BETA.1 BETA-2 ALPHA-I 
Figwe 6. Adremgic reseptor levels in left (top pa~I) and right 
(hdtem pand) ventricles. For left ventkles, subjects with a normally 
flUl&&gheart(NF)andSUl&ctswithprimarypulmoaaryhyperten- 
sion (PPH) have normal left ventricular fimctkm, whereas hkpathic 
dilated cardiomyopathy (IDC) is from subjects with end-stage h art 
failure. For right venhicles, PPH and IDC are failing and NF is 
nOrmanyfunck&g. 
adrenergic signaling in heart failure. The be&-receptor 
uncouplhtg from functional response is probably related to 
increased functional ctivity of the inhibitory Gprotein Gi 
(16,17,28,29). Chte way G proteins are measured is by toxin 
catalyzed a enosine diphosphate (ADP) ribosylation; there 
is a specitic oxin for each G protein. Pertussis toxin is the 
toxin for Cr. In Fii 10 it can be seen that in membranes 
prepared from idiopathic orischemic dilated cardiomyopa- 
thy, there is increased activity of Gt (17). This is one possible 
exphuration f r the beta.+ceptor uncoupling as G, activity 
is not changed in the failing human heart (15,16,29). 
There are at least wo and probably more receptors 
coupled tocontractihty by the inositol triphosphate pathway 
in the human heart. Figure 11 gives data on incorporation of 
radiolabeled myoinositol into inositol phosphates by alphar- 
and M2 muscarinic receptor agonists in homogenates pr -
pared from nonfailii and failing human hearts (30). The 
alpha,-agonist orepinephrine yields a very minimal stimu- 
lation that is not dikent in failing versus no&tiling hearts. 
In contrast, M2 muscarinic receptor activation mediis a 
more robust response, which is also not attenuated in heart 
failure. This difference in the alpha,-adrenergic versus M2 
muscarinic nositol phosphate responses is most likely ex- 
plained by their relative receptor densities (Fig. 12). As 
listed in Table 4, the human myocardial Mz receptor is
l .p<.O!ivsNF 
*. p < .05 “S PPH 
DA EPI NPY 
RIGliT VENTRICLES 
KL 
q PFn 
‘.p c .05 vs NF 
#.p<.O5vsPPH 
” 
N DA EPI NW 
Figure 7. Tissue catecholamine levels in the same ventricles as in 
Fii 6. DA = dopamine; EPI = epinephrine; NE = norepineph- 
rine; NPY = neuropeptide Y; other abbreviations as in Fii 6. 
coupled toboth a negative inotropic response through Giand 
a positive inotropic response througb phospholipase C (20). 
‘Ibe alpha,-mediated positive inotropic response in iso- 
Figmw 8. Beta,- and bekreceptor densities and percent inpooled 
left and right venticles from subjects with end-stage h art failure 
and idiopathic cardiomyopathy and in normal subjects. Abbrevia- 
tions as in Fiie 4. 
100 
I 
w NF. n = 72 CHAMBERS 
q F. n = 9D CHAMBERS ” ’ ’ ‘05 “’ NF 
80. 
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lated tissue is minimal compared with the beta-adrenergic 
effects and as a result it is diicult to characterize (31). This 
is explained by the low alpha,-!beta-receptor density in 
human heart. However, two groups have demonstrated a 
alpha,-receptor-mediated notropic response in isolated hu- 
man ventricle (3233) and neither has observed an attenuated 
response in heart failure (32,33). Conversely, using an intra- 
coronary technique, investigators (34) have observed an 
attenuated alpha,-response to phenylephrine in the intact 
human heart. As can be observed in Figure 13, in terms of 
dP/dt units, in nonfailing tissue the partial beta-agonist 
dobutamine produces a response of 1,200 (Fig. 5) compared 
with an alpha, response to phenylephrine of 200 to 300. The 
latter is obviously a very small positive inotropic effect (34). 
Jf the data in Fiiure 13 are considered rather than isolated 
tissue xperiments (32,33), the alpha, response isattenuated 
in heart failure. Given the preserved (30) or even increased 
alpha,-receptor density (35,36) in the failing human ventri- 
cle, this would mean that the alpha,-receptors are uncoupled 
Figure 10. Cholera toxin (0 and pert&s toxin (PI’X) catalyzed 
adenosine diphosphate ribosylation in membranes prepared from 
nonfailing (NF) lefi ventricles and ventricles from subjects with 
end-stage heart failure with idiopathic dilated cardiomyopathy (IDC) 
and ischemk d&cd cardiomyopathy (1SCDC). 
q NF.n=14 
q ISCDC, n = 9 
D IDC.ll=l2 l l 
‘.p<.O5vsNF ,T 
. 
low) 1 
-1 0 
-I- ‘pc0.05 
NF F NF F 
FQue 9. Be&-receptor density and selective be&-agonist (xam- 
oterolj-mediated r sponse in failing and nonfailing human ventri- 
cles. Abbreviations a  in Fii 4. 
beyond the level of inositol triphosphate in the failing human 
heart. 
Many other receptors in the failing heart are not 
changed, including dihydropyridine (37), ouabain (38) and 
histamine (13.14) receptors. Therefore, as shown in Table 4, 
the majority of cell surface receptors coupled to a posi- 
tive inotropic response are unchanged in heart failure. 
Figure 11. Stimulation f the incorporation f labeled myoinositol in 
phosphoinositides, inciuding inositol triphosphate (IPJ by the M2 
muscarinic agonist carbachol and the alpha,-adrenergic agonist 
norepinephrine (NE) in homogenates prepared from Wing and 
nonfailing human hearts. Abbreviations a  in Figure 4. 
-r T n NF.n=6ChREWHDLANDSNE a F.n-7 cAmAcHDLAND4NE 
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Figure 12. M2 muscatinic and alpha,-adrenergic eceptor den- 
sities in crude membranes prepared from nonfailing and failing 
human l&t ventricles. Abbreviations as in Figure 4. 
ALPHA-1 
Moreover, only two receptors, the beta,-adrenergic and VIP 
receptor, exhibit dowzwgulation i  failing ventricular myo- 
cardium. 
Ca~ofaltmdrecept0cGpr0teinc~geshthef~ 
human heart. Tire initiaring signal. Receptor regulation is
complex, but one factor accounting for altered beta- 
adrenergic receptor and Gi chaages in the failing human 
heart is chronically elevated adrenergic drive (39). This is 
based on data in both model systems imd the intact human 
heart. Chronic exposure to beta-agonists consistently pro- 
duces beta-receptor desensitization phenomena, which in- 
clude receptor uncoupling (40). downregulation (41) and 
increased activity of Gi (42). In the failing human heart, he 
degree ofadrenergic drive as assessed bycoronary sinus 
norepinephrine lev ls (43) or tissue norepinephrine depletion 
(44) correlates with beta-receptor d wnregulation. Finally, 
removal of adrenergic drive by beta-blockade (45,46) or 
partial attenuation of it by angiotensin-converting nzyme 
inhibition (47) partially reverses beta-receptor d wnregula- 
tion (43&I), and beta-blockade may reverse beta-receptor 
u=ouPW (48). 
Molecular mechanisms. The decreased density of beta*- 
adrenergic receptors in failing human ventricular myocar- 
Table 4. Receptors That Change V rsus Those That Are 
Apparently Uaaltcred in the Failing Human Heart 
Altered Unaltered 
&ra,-adreaergic olwM*ed Hz histamine 
~u-ww 
Be&&CM& (uncoupled) A, adcaosine 
VIP (downregulated) somatostatia 
AWa,-adrew# Omc0upkd~ Dihydropyrfdin 
Guabain 
M2 musciirinic (G,ewpled) 
M* IlkuSWinic @hospWpase c wupld) 
dium appears tobe related to declreased l vels of beta,- 
receptor mRNA (49). That is, quantitative polymemse chain 
reaction measurements in poly(A)+-enriched mRNA or RNase 
protection assay in total RNA extracted from failing human 
ventricles reveals comparable degrees of downregulation of 
receptor and message (49). The increase inalpha+ceptor 
density hat we reported in combined studies (36) and others 
reported in single investigations (35) may be related tocross- 
regulation phenomena, with beta-adrenergic stimulation in-
creasing alpha,-receptor tuRNA abundance (12). Candidates 
for uncoupling of be&receptors in idiopathic dilated cardio- 
myopathy (10,17) orbe&,-receptors iu ischemic cardiomyop- 
athy (17) include increased functional activity of Gi 
(16,17,2&29) and receptor phosphorylation. Wii regard tothe 
latter, beta-adrenergic receptor kinase mRNA levels and activ- 
ity have been shown to be increased in the failing human 
ventricle (50), but increased phosphorylation of beta,- or 
betarreceptors has not been demonstrated. 
The increased functional ctivity of Gi that is found in 
failing ventricles (16,17,28,29) is apparently a posttransla- 
tional modification f the alpha subunit ofGi-3, inasmuch as
alphaKii.3 mRNA abundance (51) and immunodetectable 
protein levels (18) are not different inpreparations f failing 
and no&ailing human hearts. 
Cliieal s@&ance of adreuergic recepbr chaqgs in the 
fbiiiq human heart. The major general interpretation of the 
adrenergic re eptor changes that occur in the failing human 
heart is that myocardial cells have undergone regulatory 
changes to ward off adrenergic stimulation. That is, changes 
at the level of receptors and G proteins serve to limit the 
amount ofinotropic stimulation a d biologic effect that can 
be produced through t ese pathways. However, the problem 
is that quantitatively only about 50% of the combined 
adrenergic patbways appear tobe subject to regulation, and 
despite these desensitization changes, the adrenergic path- 
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Figure 13. First derivative of left ventricular p essure (dP/ 
dt) response tophenylephrine without (panel A) and with the 
response ir the presence of a blockade with phentolamine 
subtracted (panel B) in subjects without (open bars) and with 
(&sed bars) heart failure. Reproduced from La&&erg et al. 
(34, with permission f The American Heart Association. 
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ways, particularly the beta-adrenergic pathways, are still 
capable of producing formidable effects. 
Three major components of the natural history of heart 
failure are loss of exercise tolerance, progression of Ieft 
ventricular dysfunction and an increased prevalence ofar- 
rhythmias, including a high incidence ofsudden death as the 
cause of death in 20% to 50% of subjects. It appears likely 
that the adrenergic nervous ystem and itsreceptor-effector 
mechanisms play a role in all three components. Asshown in 
Figure 14, the desensitization changes that occur in adren- 
ergic receptor pathways limit the functional capacity of the 
failing heart by compromising its s imulated function capa- 
bility. In contrast, because approximately 50% of the adren- 
ergic pathway remains functiona! inthe failing heart, chron- 
ically increased adrenergic stimulation provides an 
explanation for progressive pump dysfunction by virtue of a 
generally cardiotoxtc mechanism. This is presumably why 
beta-blockade consistently improves left ventricular fimc- 
tion in subjects with heart failure (45,46,52). 
Vascular Receptors 
There is less information from the standpoint of vascular 
receptors in heart failure, but the general conclusion isthat 
relatively few changes occur. Fiiure I5 displays data from a 
forearm blood flow study reported by Creager tal. (53) in 
Figure 14. Dual adierse ffects of chronically elevated car- 
diac adrenergic drive. NE = norepinephrine. 
10-6 fO+ bADRENERGlC COMPONENT) 
FHEff YL EPnRmE CONCENTRATION lmatarl 
normal subjects and patients with hear  failure; thele is no 
difference in beta-agonist response. In other words, there 
appears to be no desensi+&tion f the peripheral vascuhu 
beta-receptor pathway in heart failure. Interestingly, there 
are no good pharmacologic data on the status of the periph- 
eral vascular alpha,-receptor pathway in heart failure. Gold- 
smith et al. (54) reported hemodynamic data for systemic 
infusions of norepinephrine i  subjects with heart failure 
without concomitant control subjects. In this study, norepi- 
nephrine was increased to a level of 2,500 pg/ml without 
producing an effect on blood pressure or heart rate. Similar 
increases innorepinephrine  normal human subjects along 
with an increase in blood pressure and a reflex decrease in
heart rate have been observed by others (55). Therefore, it
may be that he peripheral vascular alpha,-receptor pathway 
is partially desensitized in heart failure. Postsynaptic alpha,- 
receptors are also present i  vascular tissue, and the only 
data in heart failure are from Kubo et aI. (56), who reported 
that the alpha,-blocker yohimbine produced comparable 
increases inforearm blood flow in heart failure. 
Conclusions 
Most of the changes that occur in adrenergic receptor 
pathways in heart failure appear to occur in the beart. In 
ventricular myocardium, receptor pathway changes are ob 
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Forearm blood flow response totbe beta-agonist isopro- 
terenol insubjects with heart failure and normal control subjects. 
Reproduced from Creager et al. (53), with permission of The 
American Heart Association. 
served only in failing chambers. The implication of this is 
that the myocardii changes are under local or regional 
control; that is, they are not related to systemic factors. Of 
the changes in myocardial adrenergic receptors, beta- 
receptor phenomena ar: the most striking, and of the 
changes in beta-adrenergic eceptors, beta,-receptor d wn- 
regulation is the most prominent. Most of the changes in 
adrenergic receptors appear to be related to increased ad- 
renergic drive. However, eceptor regulation is very com- 
plicated and increased adrenergic drive is probably only a 
partial explanation for these changes. 
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